Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Neurimmune is a Swiss biopharmaceutical company focused on the discovery and development of novel human-derived therapeutic antibodies for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and frontotemporal dementia. The company leverages its proprietary Reverse Translational Medicine™ (RTM™) technology platform, which identifies therapeutic candidates by analyzing the human immune system's response to disease. Neurimmune has a pipeline of promising drug candidates and has established significant collaborations with major pharmaceutical companies to advance its innovative therapies.
Serves as the primary center for research and development, corporate operations, and strategic decision-making.
Located within the Bio-Technopark Schlieren-Zürich, a leading Swiss innovation hub for life sciences, providing state-of-the-art laboratory and office facilities.
Characterized by a strong emphasis on scientific innovation, collaboration, precision, and a patient-driven mission to combat neurodegenerative diseases.
Strategically positioned in a major European biotechnology cluster, offering access to a skilled talent pool, research institutions, and global connectivity.
While Neurimmune's primary operations are centralized at its headquarters in Switzerland, its global presence is established through international collaborations with pharmaceutical partners, clinical trials conducted across multiple countries, and the potential worldwide impact of its therapeutic candidates. Its research and therapies aim to address global health challenges in neurodegenerative diseases.
Wagistrasse 13
Schlieren
Zurich
Switzerland
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Neurimmune AG' leadership includes:
Neurimmune AG has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major announced executive hires or exits at Neurimmune in the last 12-18 months, suggesting stability in the core leadership team. The company continues to build its broader team as programs advance.
Discover the tools Neurimmune AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Neurimmune likely uses common corporate email formats. The most probable formats are [first_initial][last]@neurimmune.com or [first].[last]@neurimmune.com.
[first].[last]@neurimmune.com
Format
roger.nitsch@neurimmune.com
Example
85%
Success rate
neurimmune.com (Press Release) • October 26, 2023
Neurimmune and Ono Pharmaceutical Co., Ltd. announced they have entered into a second collaboration agreement to discover and develop novel antibody therapeutics for neurodegenerative diseases. This partnership will leverage Neurimmune's proprietary RTM™ Technology Platform to generate antibodies against new targets....more
globenewswire.com (Biogen Press Release) • January 05, 2023
The U.S. Food and Drug Administration (FDA) granted accelerated approval for LEQEMBI™ (lecanemab-irmb), an Alzheimer's disease treatment. Lecanemab was developed by Eisai in partnership with Biogen, based on an antibody originally discovered through Neurimmune's RTM™ platform (antibody Bapineuzumab, further developed into Lecanemab). This marks a significant milestone for therapies derived from Neurimmune's foundational research....more
neurimmune.com (News) • March 21, 2024
Neurimmune announced it would present new preclinical data on its antibody candidates for Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS) at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Neurimmune AG, are just a search away.